VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 1, 2008) - Allon Therapeutics Inc. (TSX:NPC) presented preclinical data today that demonstrate the potential of the Company’s proprietary product candidate AL-309 as a treatment for peripheral neuropathy. AL-309 is the lead candidate in Allon’s second neuroprotection technology platform, derived from Activity Dependent Neurotrophic Factor (ADNF).
